EBNA1BP2

Summary

EBNA1BP2 (EBNA1 binding protein 2, HGNC:15531) is a protein-coding gene on chromosome 1p34.2, encoding Probable rRNA-processing protein EBP2 (Q99848). Required for the processing of the 27S pre-rRNA. It is a common-essential gene (DepMap: required in 98.0% of cancer cell lines).

Enables RNA binding activity. Predicted to be involved in rRNA processing and ribosomal large subunit biogenesis. Located in chromosome and nucleolus.

Source: NCBI Gene 10969 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 49 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 98.0% of screened cell lines (common-essential)
• MANE Select transcript: NM_006824

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15531
Approved symbol	EBNA1BP2
Name	EBNA1 binding protein 2
Location	1p34.2
Locus type	gene with protein product
Status	Approved
Aliases	NOBP, EBP2, P40
Ensembl gene	ENSG00000117395
Ensembl biotype	protein_coding
OMIM	614443
Entrez	10969

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 7 protein_coding_CDS_not_defined, 4 protein_coding

ENST00000236051, ENST00000431635, ENST00000461557, ENST00000463906, ENST00000466927, ENST00000472982, ENST00000474566, ENST00000483082, ENST00000491223, ENST00000894725, ENST00000954564

RefSeq mRNA: 2 — MANE Select: NM_006824 NM_001159936, NM_006824

CCDS: CCDS478, CCDS53308

Canonical transcript exons

ENST00000236051 — 9 exons

Exon	Start	End
ENSE00001080522	43172053	43172290
ENSE00001080525	43164184	43164493
ENSE00001189528	43170756	43170879
ENSE00003485480	43167160	43167235
ENSE00003583248	43168939	43169028
ENSE00003589524	43171479	43171651
ENSE00003641116	43164643	43164805
ENSE00003644947	43166826	43166919
ENSE00003678448	43171886	43171969

Expression profiles

Bgee: expression breadth ubiquitous, 291 present calls, max score 97.75.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 62.1031 / max 454.9824, expressed in 1821 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12022	61.1709	1821
12023	0.3604	166
12027	0.2663	134
12021	0.2123	73
12020	0.0795	17
12019	0.0093	4
12026	0.0043	4

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	97.75	gold quality
adenohypophysis	UBERON:0002196	96.54	gold quality
tendon of biceps brachii	UBERON:0008188	95.68	gold quality
pituitary gland	UBERON:0000007	95.53	gold quality
right testis	UBERON:0004534	95.24	gold quality
left testis	UBERON:0004533	95.09	gold quality
right frontal lobe	UBERON:0002810	94.85	gold quality
calcaneal tendon	UBERON:0003701	94.60	gold quality
islet of Langerhans	UBERON:0000006	94.50	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.44	gold quality
tendon	UBERON:0000043	94.31	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.26	gold quality
right uterine tube	UBERON:0001302	94.14	gold quality
cortical plate	UBERON:0005343	94.06	gold quality
testis	UBERON:0000473	93.87	gold quality
cingulate cortex	UBERON:0003027	93.87	gold quality
anterior cingulate cortex	UBERON:0009835	93.84	gold quality
body of pancreas	UBERON:0001150	93.73	gold quality
metanephros cortex	UBERON:0010533	93.71	gold quality
rectum	UBERON:0001052	93.70	gold quality
right adrenal gland	UBERON:0001233	93.69	gold quality
left adrenal gland	UBERON:0001234	93.65	gold quality
left adrenal gland cortex	UBERON:0035825	93.65	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.64	gold quality
esophagus mucosa	UBERON:0002469	93.59	gold quality
caudate nucleus	UBERON:0001873	93.55	gold quality
right adrenal gland cortex	UBERON:0035827	93.53	gold quality
mucosa of transverse colon	UBERON:0004991	93.51	gold quality
nucleus accumbens	UBERON:0001882	93.47	gold quality
frontal pole	UBERON:0002795	93.44	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	57.20
E-HCAD-13	yes	20.51
E-CURD-112	yes	8.59
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYC, RB1

miRNA regulators (miRDB)

12 targeting EBNA1BP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-6126	99.62	68.09	996
HSA-MIR-3978	99.24	68.39	2201
HSA-MIR-520G-3P	98.91	67.38	1914
HSA-MIR-520H	98.91	67.38	1914
HSA-MIR-3908	98.75	67.31	1160
HSA-MIR-10395-3P	98.10	66.70	1726
HSA-MIR-4680-5P	96.43	67.15	893

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 98.0% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 8)

• attaches to yeast mitotic chromosomes in a cell cycle-dependent manner and causes EBNA1 to attach to the mitotic chromosomes and effect EBV plasmid segregation (PMID:12768013)
• Data show that human EBNA1 binding protein 2 (hEBP2 is essential for the proliferation of human cells and that repression of hEBP2 severely decreases the ability of EBNA1 and EBV-based plasmids to bind mitotic chromosomes. (PMID:15923612)
• RNA and protein levels of cyclin E1, a dominant oncoprotein, were elevated in the EBP2- enhanced green fluorescent protein stable clones. (PMID:18959818)
• BXDC1 and EBNA1BP2 function in a dynamic scaffold for ribosome biogenesis. (PMID:19170763)
• EBP2 is a novel binding partner of c-Myc that regulates cell proliferation, and tumorigenesis via a positive feedback loop. (PMID:24481446)
• We further show that the primary tumors as well as metastasized lesions derived from EBV antigen-expressing cancer cells( EBNA3C or EBNA1 ) in nude mice model display EMT markers expression pattern (PMID:25501510)
• Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. (PMID:30224479)
• EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53. (PMID:33040459)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ebna1bp2	ENSDARG00000054980
mus_musculus	Ebna1bp2	ENSMUSG00000028729
rattus_norvegicus	Ebna1bp2	ENSRNOG00000045760
drosophila_melanogaster	CG1542	FBGN0039828
caenorhabditis_elegans		WBGENE00015941

Protein

Protein identifiers

Probable rRNA-processing protein EBP2 — Q99848 (reviewed: Q99848)

Alternative names: EBNA1-binding protein 2, Nucleolar protein p40

All UniProt accessions (3): Q99848, H7C2Q8, Q6IB29

UniProt curated annotations — full annotation on UniProt →

Function. Required for the processing of the 27S pre-rRNA.

Subunit / interactions. Specifically interacts with EBV EBNA1. The EBNA1-EBP2 interaction is important for the stable segregation of EBV episomes during cell division. Interacts with WDR46.

Subcellular location. Nucleus. Nucleolus.

Tissue specificity. Ubiquitous.

Similarity. Belongs to the EBP2 family.

RefSeq proteins (2): NP_001153408, NP_006815* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008610	Ebp2	Family

Pfam: PF05890

UniProt features (20 total): modified residue 9, region of interest 3, cross-link 3, chain 1, sequence variant 1, sequence conflict 1, coiled-coil region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
8FKV	ELECTRON MICROSCOPY	2.47
8FKW	ELECTRON MICROSCOPY	2.5
8FKX	ELECTRON MICROSCOPY	2.59
8FKY	ELECTRON MICROSCOPY	2.67
8FKQ	ELECTRON MICROSCOPY	2.76
8FKT	ELECTRON MICROSCOPY	2.81
8FKU	ELECTRON MICROSCOPY	2.82
8FKP	ELECTRON MICROSCOPY	2.85
8FKS	ELECTRON MICROSCOPY	2.88
8FKR	ELECTRON MICROSCOPY	2.89

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99848-F1	76.02	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (12): 11, 13, 16, 264, 270, 94, 179, 218, 1, 3, 7, 9

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6791226	Major pathway of rRNA processing in the nucleolus and cytosol

MSigDB gene sets: 170 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, MORF_DNMT1, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, GOBP_RIBOSOME_BIOGENESIS, BASSO_B_LYMPHOCYTE_NETWORK, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, KENNY_CTNNB1_TARGETS_UP, CAGCTG_AP4_Q5, EFC_Q6, SCHUHMACHER_MYC_TARGETS_UP, GGAANCGGAANY_UNKNOWN, chr1p34, GARY_CD5_TARGETS_DN, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN

GO Biological Process (3): rRNA processing (GO:0006364), ribosomal large subunit biogenesis (GO:0042273), ribosome biogenesis (GO:0042254)

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (5): chromosome (GO:0005694), nucleolus (GO:0005730), preribosome, large subunit precursor (GO:0030687), nuclear periphery (GO:0034399), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
rRNA processing in the nucleus and cytosol	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ribosome biogenesis	2
ribonucleoprotein complex biogenesis	2
intracellular membraneless organelle	2
nuclear lumen	2
RNA processing	1
rRNA metabolic process	1
nucleic acid binding	1
binding	1
preribosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2972 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EBNA1BP2	RPF2	Q9H7B2	867
EBNA1BP2	PWP1	Q13610	860
EBNA1BP2	WDR12	Q9GZL7	853
EBNA1BP2	DDX21	Q9NR30	826
EBNA1BP2	WDR74	Q6RFH5	806
EBNA1BP2	PDCD11	Q14690	789
EBNA1BP2	DDX56	Q9NY93	767
EBNA1BP2	NIP7	Q9Y221	757
EBNA1BP2	NOP2	P46087	744
EBNA1BP2	GNL2	Q13823	735
EBNA1BP2	SURF6	O75683	710
EBNA1BP2	RSL24D1	Q9UHA3	687
EBNA1BP2	NIFK	Q9BYG3	670
EBNA1BP2	GNL3	Q9BVP2	661
EBNA1BP2	RRP15	Q9Y3B9	657

IntAct

209 interactions, top by confidence:

A	B	Type	Score
BRIX1	EBNA1BP2	psi-mi:“MI:0915”(physical association)	0.810
EBNA1BP2	BRIX1	psi-mi:“MI:0915”(physical association)	0.810
SRP68	SRP72	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
NOP53	RRP8	psi-mi:“MI:0914”(association)	0.640
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
NPM1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.610
CEP70	EBNA1BP2	psi-mi:“MI:0915”(physical association)	0.560
FAM9B	EBNA1BP2	psi-mi:“MI:0915”(physical association)	0.560
ING4	KAT7	psi-mi:“MI:0914”(association)	0.530
RPS6	IPO7	psi-mi:“MI:0914”(association)	0.530
RRP8	NVL	psi-mi:“MI:0914”(association)	0.530
RPL37A	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
MACROH2A2	PPM1G	psi-mi:“MI:0914”(association)	0.530
PRR11	NVL	psi-mi:“MI:0914”(association)	0.530
MAK16	NVL	psi-mi:“MI:0914”(association)	0.530
KNOP1	DHX15	psi-mi:“MI:0914”(association)	0.530
PUM3	RRP8	psi-mi:“MI:0914”(association)	0.530
PDGFB	DKC1	psi-mi:“MI:0914”(association)	0.530
H1-6	ZNF724	psi-mi:“MI:0914”(association)	0.530
MAGEB2	POLRMT	psi-mi:“MI:0914”(association)	0.530
ZC3HAV1	KHNYN	psi-mi:“MI:0914”(association)	0.530
H2AC20	PPM1G	psi-mi:“MI:0914”(association)	0.530
RBM4	NVL	psi-mi:“MI:0914”(association)	0.530

BioGRID (470): FAM9B (Two-hybrid), EBNA1BP2 (Affinity Capture-MS), EBNA1BP2 (Affinity Capture-MS), EBNA1BP2 (Affinity Capture-MS), EBNA1BP2 (Affinity Capture-MS), EBNA1BP2 (Affinity Capture-MS), RPL34 (Affinity Capture-MS), RPL3 (Affinity Capture-MS), HSPA8 (Affinity Capture-MS), RPL6 (Affinity Capture-MS), HIST1H1A (Affinity Capture-MS), HIST1H1E (Affinity Capture-MS), NPM1 (Affinity Capture-MS), RPL8 (Affinity Capture-MS), DDX21 (Affinity Capture-MS)

ESM2 similar proteins: A4R1G4, A5DLD1, A6QNR1, A6QR31, A6RKG5, A6ZZL7, A7E4K0, A7SL20, B2RYG1, B5VM59, B6HGB5, B6K8A0, C4Y4A0, C7YTL6, C9S8J9, D5GA77, P0CR21, P34247, P78794, Q09462, Q09867, Q09958, Q0V389, Q10106, Q3UFY0, Q55C50, Q5R9E5, Q5RAS1, Q5RJT2, Q5ZKM1, Q6BGV5, Q6CFU2, Q6CXA6, Q6DRJ4, Q752L7, Q75A47, Q75D81, Q8IY81, Q96EU6, Q99848

Diamond homologs: O13802, P36049, Q09958, Q99848, Q9D903, Q9I8J6, Q9LUJ5, Q9V9Z9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 214 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SRP-dependent cotranslational protein targeting to membrane	16	12.2×	9e-11
Selenocysteine synthesis	13	11.9×	7e-09
Eukaryotic Translation Initiation	5	11.8×	2e-03
Cap-dependent Translation Initiation	5	11.8×	2e-03
SARS-CoV-1 modulates host translation machinery	5	11.8×	2e-03
Peptide chain elongation	12	11.6×	4e-08
Viral mRNA Translation	12	11.6×	4e-08
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	12	11.5×	4e-08

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of transcription by RNA polymerase I	5	17.7×	7e-04
cytoplasmic translation	15	15.2×	3e-11
ribosomal large subunit biogenesis	6	14.5×	3e-04
rRNA processing	18	13.9×	7e-13
ribosomal small subunit biogenesis	11	13.7×	1e-07
regulation of alternative mRNA splicing, via spliceosome	8	10.7×	1e-04
regulation of signal transduction by p53 class mediator	5	10.5×	6e-03
negative regulation of viral genome replication	5	10.2×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

49 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	32
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

5391 predictions. Top by Δscore:

Variant	Effect	Δscore
1:43164489:CTCTT:C	acceptor_gain	1.0000
1:43164491:CTT:C	acceptor_gain	1.0000
1:43164494:C:CC	acceptor_gain	1.0000
1:43164641:A:AC	donor_gain	1.0000
1:43164642:C:CC	donor_gain	1.0000
1:43164644:TTTG:T	donor_gain	1.0000
1:43164801:TGGGC:T	acceptor_gain	1.0000
1:43164803:GGC:G	acceptor_gain	1.0000
1:43164806:C:CA	acceptor_loss	1.0000
1:43164806:C:CC	acceptor_gain	1.0000
1:43164807:T:A	acceptor_loss	1.0000
1:43166824:ACC:A	donor_gain	1.0000
1:43166825:CCC:C	donor_gain	1.0000
1:43166830:T:TA	donor_gain	1.0000
1:43166836:T:C	donor_gain	1.0000
1:43166916:AAGCC:A	acceptor_loss	1.0000
1:43166917:AGCCT:A	acceptor_loss	1.0000
1:43166918:GCC:G	acceptor_loss	1.0000
1:43166919:CCTG:C	acceptor_loss	1.0000
1:43166920:C:CC	acceptor_gain	1.0000
1:43166920:C:CG	acceptor_loss	1.0000
1:43166921:T:A	acceptor_loss	1.0000
1:43167155:CCAA:C	donor_loss	1.0000
1:43167156:CAA:C	donor_loss	1.0000
1:43167157:AAC:A	donor_loss	1.0000
1:43167158:ACCT:A	donor_loss	1.0000
1:43167159:C:T	donor_loss	1.0000
1:43167159:CCTTT:C	donor_gain	1.0000
1:43168976:G:C	donor_gain	1.0000
1:43169029:C:CC	acceptor_gain	1.0000

AlphaMissense

2005 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:43170777:T:A	K142N	0.997
1:43170777:T:G	K142N	0.997
1:43170763:A:G	M147T	0.996
1:43164769:A:C	F248L	0.995
1:43164769:A:T	F248L	0.995
1:43164771:A:G	F248L	0.995
1:43170783:C:A	M140I	0.995
1:43170783:C:G	M140I	0.995
1:43170783:C:T	M140I	0.995
1:43168967:A:G	L170P	0.994
1:43170869:C:G	A112P	0.994
1:43168954:C:A	R174S	0.993
1:43168954:C:G	R174S	0.993
1:43168964:C:G	R171P	0.993
1:43170790:G:T	A138E	0.993
1:43171491:C:G	R104P	0.993
1:43171606:A:G	W66R	0.993
1:43171606:A:T	W66R	0.993
1:43170792:A:C	F137L	0.992
1:43170792:A:T	F137L	0.992
1:43170794:A:G	F137L	0.992
1:43170762:C:A	M147I	0.991
1:43170762:C:G	M147I	0.991
1:43170762:C:T	M147I	0.991
1:43170778:T:A	K142I	0.990
1:43170779:T:C	K142E	0.990
1:43164781:T:A	K244N	0.989
1:43164781:T:G	K244N	0.989
1:43168958:A:G	L173P	0.989
1:43169015:A:G	L154P	0.989

dbSNP variants (sampled 300 via entrez): RS1000165339 (1:43170516 C>T), RS1001063133 (1:43165994 T>C), RS1001410962 (1:43166274 A>G), RS1001461199 (1:43165203 T>C), RS1001513304 (1:43164719 T>C,G), RS1001855635 (1:43163701 G>T), RS1002075195 (1:43171212 T>C), RS1002415553 (1:43169784 C>T), RS1002518071 (1:43166371 G>A), RS1002747764 (1:43171209 T>C), RS1003136685 (1:43172396 C>A,G), RS1003198743 (1:43173168 C>T), RS1003321053 (1:43164969 A>G), RS1003833059 (1:43166728 T>C), RS1004084840 (1:43174391 A>G)

Disease associations

OMIM: gene MIM:614443 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009391_619	Metabolite levels	7.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009793	isoleucine measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066269 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.37	Kd	43.16	nM	CHEMBL5653589
7.37	ED50	43.16	nM	CHEMBL5653589
6.53	Kd	298.9	nM	CHEMBL3752910
6.53	ED50	298.9	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148277: Binding affinity to human EBNA1BP2 incubated for 45 mins by Kinobead based pull down assay	kd	0.0432	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148277: Binding affinity to human EBNA1BP2 incubated for 45 mins by Kinobead based pull down assay	kd	0.2989	uM

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, affects cotreatment	6
Cyclosporine	decreases expression, increases expression, increases methylation	3
bisphenol A	decreases expression	2
cobaltous chloride	decreases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	2
Tretinoin	decreases expression	2
Aflatoxin B1	affects cotreatment, decreases expression, increases methylation	2
TAK-243	increases sumoylation	1
deoxynivalenol	increases expression	1
sodium arsenite	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
chloropicrin	decreases expression	1
deguelin	decreases expression	1
ICG 001	decreases expression	1
2-amino-14,16-dimethyloctadecan-3-ol	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
LDN 193189	decreases expression, affects cotreatment	1
(+)-JQ1 compound	decreases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Antimycin A	decreases expression	1
Atrazine	decreases expression	1
Benztropine	affects cotreatment, decreases expression	1
Cisplatin	decreases expression	1
Cuprizone	decreases expression, affects cotreatment	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Hydrogen Peroxide	affects expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651319	Binding	Binding affinity to human EBNA1BP2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.